Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study

Davide Caimmi; Abdelilah Abouelfath; R. Lassalle; S. Lignot-Maleyran; E. Bignon; Patrick Blin; Evangéline Clark; J. Cottet; Laure Carcaillon‐Bentata; Pascal Demoly

doi:10.1111/all.70270

March 8, 2026AllergyOpen Access

Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the perceived benefits of sublingual immunotherapy (NPP-SLIT) in patients with allergic rhinitis and asthma.
Conducted a real-world cohort study involving patients undergoing sublingual immunotherapy.
Collected data on patient-reported benefits and expectations over time.
Analyzed findings to connect patient expectations with clinical outcomes.
Patients reported sustained and clinically meaningful benefits from NPP-SLIT.
The findings support the use of patient-reported benefits as a valuable endpoint in allergy treatments.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Cohort study reveals patient benefits from sublingual immunotherapy in allergic rhinitis and asthma, indicating improved allergy care.

Abstract

NPP-SLIT provides sustained, clinically meaningful benefit from the patient's perspective in both age groups. ERAPP supports the PBI as a complementary endpoint that links patient expectations to outcomes and informs patient-centered allergy care.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Caimmi et al. (2026) studied this question.

synapsesocial.com/papers/69af959570916d39fea4d463 https://doi.org/10.1111/all.70270

View Full Paper

Ask AI

Bookmark

Share

Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading